11/08/04:
Tracking Wall Street Trends
SUSIE GHARIB: Wall Street is still running its own version of
the New York City marathon. The Dow rose for the fourth straight session
today and the NASDAQ made it six in a row. But does the market have enough
upward momentum to make significant gains by the year end finish line?
Erika Miller checks the pulse on Wall Street.
ERIKA MILLER, NIGHTLY BUSINESS REPORT CORRESPONDENT: It`s been a terrific
few weeks for the stock market. The Dow, the NASDAQ and the Standard &
Poor`s 500 have all gained more than 6 percent in two weeks. And some
market strategists say the coast is now clear for the market to move
higher.
JOSEPH QUINLAN, CHIEF MARKET STRATEGIST, BANC OF AMERICA CAPITAL MGMT: I
think the biggest issue was getting these big events behind us: the
Democratic, Republican conventions; the Olympics; and then now the
presidential elections and so, we`ve got some clarity.
MILLER: Investors are also relieved that the price of oil has fallen back
below $50 a barrel after peaking around the $55 mark. And if history is
any guide, the market could be entering a sweet spot. November, December
and January are statistically the best three months for the Standard &
Poor`s 500 index. Since 1950, the index has risen an average of 1.7
percent in November and in December and slightly less in January. Some
market strategists say it all adds up to a nice year end bounce.
RICHARD MCCABE, CHIEF MARKET ANALYST, MERRILL LYNCH: I think we`re going
to see further gains between now and December 31. I don`t mean to imply a
runaway. It may be a step-by-step advance. But I think we`ve turned the
corner in this famous year-end rally.
MILLER: But there are still plenty of questions about where the market
heads in 2005. Among the top concerns is slowing profit growth. Ninety
percent of S&P 500 firms have reported third quarter numbers. So far,
profits are running about 17 percent ahead of last year. But earnings
growth is expected to fall in the next three quarters. Another big concern
is rising interest rates. The Federal Reserve is widely expected to raise
short-term interest rates by .25 percent point on Wednesday and more hikes
are forecast down the road.
MCCABE: I think that temporarily the stock market can live with that.
However, as we go through 2005 and if rates continue to rise, then of
course it may become more of a problem.
MILLER: Many market strategists are already predicting that 2005 is likely
to be a volatile year. Some are even warning that it could be a down year
for stocks, a common trend in post-election years. Erika Miller, NIGHTLY
BUSINESS REPORT, New York.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may be
posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly Business
Report is not and should not be considered as investment advice.
Copyright (c) 2004 Community Television Foundation of South
Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/08/04:
One On One With Michael Panantonio, Sr. Partner With Levin Panantonio
SUSIE GHARIB: Merck said today it is being investigated by the Department of
Justice regarding its Vioxx research and marketing practices. The drug
maker says it`s also the target of an informal SEC inquiry. Meanwhile,
hundreds of lawyers are meeting this week in Las Vegas to launch a major
legal assault against Merck. They represent people who were injured or
killed by Merck`s painkiller drug, Vioxx.
Joining us now, the attorney who organized the meeting: Michael Papantonio,
senior partner with Levin and Papantonio. Hi Mike. Nice to have you on the
program.
J. MICHAEL PAPANTONIO, ATTORNEY, LEVIN-PAPANTONIO: How are you doing?
GHARIB: I`m fine thank you. So tell us why are you and the other 700
lawyers meeting this week in Las Vegas? Are you trying to pull together a
class-action status to these lawsuits?
PAPANTONIO: This is probably the biggest litigation that`s happened in the
pharmaceutical industry since phen-fen and this is just an opportunity for
lawyers to get together and really organize how they`re going to go to
battle with Merck. It is going to be a long protracted battle and so this
is the opportunity for everybody to sit down and say, to map out a strategy
more than anything. Merck has some big problems with this case, Susie.
This is not something that`s going to go away overnight. You know, they
understood four years ago the problem that they might be facing, and now
sure it`s come to pass.
GHARIB: How many cases are you talking about? How many cases are all of
your lawyers dealing with?
PAPANTONIO: It`s hard to say. The FDA says that right now 20,000 to 27,000
people either had strokes or heart attacks because of Vioxx. Typically
they`re under tremendously. The FDA`s projections are always ridiculously
low. These numbers could run as high as 50,000 to 100,000 as far as cases
that are directly related to Vioxx users.
GHARIB: Mike, how are you going to prove damage here? Because from what I
understand, a lot of the people who were patients using Vioxx were an older
population, had other risk factors. So it seems like it`s less defined,
the cause and relationship.
PAPANTONIO: That`s what Merck would like everybody to believe, but the
cases that we are seeing are just as common between a 47 to 55-year-old
who`s very athletic. They run. Their health is important to them. Many of
them are taking Vioxx because of they had aches and pains related to all
that exercise. So that`s not accurate at all. The strongest cases we are
seeing are people that were very, very athletic. And the causation issue
just is not a problem in this case at all. Especially you take the
documents that have been put together in this case. I`ve been (ph) doing
this, 25 years, pharmaceutical litigation for 25 years. I really don`t
believe I`ve ever seen documents, these kinds of smoking guns in any one
case.
GHARIB: What kind of documents are you talking about?
PAPANTONIO: Well, it`s documents that show as far back as 1999, the company
absolutely knew that the product had the ability to cause a heart attack
and a stroke. They covered that up. They went through 2000, 2001, four
studies all saying the same thing, that the product you`re selling to
American consumers has the ability to kill people and cripple them. They
ignored it. While they were ignoring it in fact, they were pumping up
their marketing. They spent $200 million marketing a product that
everybody inside knew was dangerous. This is bad corporate decisions. And
unfortunately the people that are going to pay or the stock brokers, the
stock holders.
GHARIB: What about the responsibility from the FDA? Considering that this
drug had been approved by the FDA, does that reduce the product liability
of the company?
PAPANTONIO: Not at all. This FDA, for the last four years, has been the
most useless agency. And you know what? It`s useless to this degree.
Corporate America is hit and hurt because this FDA doesn`t do its job.
Consumers are hurt and hit because this FDA can`t do its job. It is merely
an arm of the pharmaceutical industry and the pharmaceutical industry
thinks that`s good for them. Let me show you something. Merck.
GHARIB: I`m afraid we`re going to have to leave it there, Mike. We`ve run
out of time so we`re going to have to wrap it up. But thank you so much
for coming on the program and talking to us. We appreciate it. We`ve been
speaking with Michael Papantonio of Levin-Papantonio.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may be
posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly Business
Report is not and should not be considered as investment advice.
Copyright (c) 2004 Community Television Foundation of South
Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/08/04:
A New Blood Test Is Underway
PAUL KANGAS: There has never been a substitute for blood until now. Some trauma
centers throughout the U.S. are testing a blood substitute that could be
on the market in a few years. As Diane Eastabrook reports, this medical
breakthrough could change emergency medical care and save thousands of
lives.
DIANE EASTABROOK, NIGHTLY BUSINESS REPORT CORRESPONDENT: At an accident
scene, seconds count. Victims can`t get blood transfusions until they
reach hospitals. But soon patients will start getting a blood substitute
on their way there. Northfield Laboratories in suburban Chicago is doing
final clinical trials on a blood substitute called polyheme. Polyheme is
derived from human blood that has been stripped of hemoglobin. The
hemoglobin is then purified and chemically treated, so it can carry oxygen
through the body just like blood. But unlike blood, polyheme doesn`t have
to be typed or cross-matched and it has a much longer shelf life.
DR. STEVEN GOULD, CHAIRMAN & CEO, NORTHFIELD LABORATORIES: Our product
provides for immediate replacement of lost oxygen- carrying capacity, so we
have the potential to improve survival in critically injured patients and
thereby transform the treatment of trauma in this country and throughout
the world.
EASTABROOK: Loyola University medical center near Chicago, and 15 other
trauma centers across the U.S. will be testing polyheme over the next year.
Paramedics in the air and on the ground will administer the blood
substitute to critically injured patients. Before Loyola University
medical center began the polyheme study, it spent months training its own
staff and local emergency medical service units on how to use the blood
substitute. It also had to go out to area communities and educate the
public about the product.
DR. RICHARD GAMELLI, LOYOLA UNIVERSITY MEDICAL CENTER: For a lot of it, it
was like it seemed obvious. Why wouldn`t we do this? And so that was
almost surprising on my part. I thought maybe there would be a lot more
skepticism about (INAUDIBLE), but it was important, I think, for them to
want to get educated about what the problem was, and for them to understand
what we are attempting to do.
EASTABROOK: Northfield Laboratories has been developing polyheme for nearly
20 years. During that time, close to a dozen other firms, including Baxter
Laboratories, developed competing products but most abandoned them in
earlier trials. Industry watchers are optimistic polyheme will prove
successful in the current trial. But some say even with good results,
getting FDA approval could be challenging.
BENJAMIN ANDREW, MEDICAL DEVICE ANALYST, WILLIAM BLAIR & COMPANY: There is
nothing more fundamental to life than the blood that everybody has. We
have a good product today. It`s safe. It`s well- characterized, we know a
lot about it. Anything different than that that you are trying to use as a
drug, you`d have to prove that it is every bit as good as what you
currently have.
EASTABROOK: Northfield Labs says once approved polyheme will only be used
to treat trauma. But the company says the product could eventually be used
to treat heart attacks and strokes as well. Diane Eastabrook, NIGHTLY
BUSINESS REPORT, Mt. Prospect, Illinois.
To Learn More about this topic, click
here.
Nightly Business Report transcripts are available
on-line post broadcast. The program is transcribed by eMediaMillWorks.
Updates may be posted at a later date. The views of our guests
and commentators are their own and do not necessarily represent
the views of Community Television Foundation of South Florida,
Inc. Nightly Business Report, or WPBT. Information presented
on Nightly Business Report is not and should not be considered
as investment advice. Copyright (c) 2004 Community Television
Foundation of South Florida, Inc. ALL RIGHTS RESERVED. Terms
of use.
11/08/04:
Sir Harold Evans Shares A Sneak Preview of "They Made America"
SUSIE
GHARIB: Sir Harold Evans, the renowned journalist and author,
comes to public television tonight. His special series, called
"They Made America," profiles the immigrants, gamblers and rebels
whose innovations made America. I recently spoke with Evans
and asked him what`s the message of his series.
SIR HAROLD EVANS, AUTHOR, THEY MADE AMERICA: America has
been dominate in innovation over 200 years. How did it move
from a rural society which was against manufacturing to become
the economic powerhouse? How did it do it? It did it by these
people, the innovators.
GHARIB: Sir Harry, many of the innovators that you feature
are not household names, and yet to use the title of your
series, "They Made America. How did you select them? What
did they have to measure up to?
EVANS: They had to be, have made a significant contribution
to the way we live, not making money, that`s completely secondary.
Electricity, television, the radio, the cell phone, they made
a difference to our lives and that was the most important
thing. I chose them by surveying them over more than a year
and picking on those that made the biggest contribution representative
of gender differences, racial differences and time periods.
GHARIB: And they come from so many different fields: from
Ruth Handler who created the Barbie doll, to Thomas Watson,
Jr., of IBM. What would you say are the common traits of the
greatest innovators?
EVANS: I think persistence is one of the common traits of
the greatest innovators because most of them meet with derision.
People trying to destroy them before they`ve even get going,
because everybody`s used to the status quo and nobody likes
change. So persistence is one. Secondly, willing to be second
but to know that what you`re going to do after somebody else
is better. And the third, which is the dominant theme in this
series we`ve made for WGBH, is democratization. These people
enlarged American democracy by making things available to
the many that were previously available only to the few.
GHARIB: You say in your book that someone might be a famous
inventor, but he`s not necessarily an innovator. What is the
difference?
EVANS: Many, many inventions never yield anything. You see
Alexander Graham Bell invented the telephone. But he didn`t
actually innovate it because his telephone didn`t work, and
it was left to Theodore Vail and Thomas Edison to make it
work. In other words, an innovator is somebody who makes practical
use of an original idea.
GHARIB: The first segment is called "The Rebels," and you
feature Ted Turner who created CNN and Russell Simmons, the
brainchild behind the Def Jam record label. Why are they rebels?
EVANS: Ted Turner was rebelling against the stranglehold
of the commercial television networks, who said you could
never work with 24 hours. He really rebelled against that.
And Russell Simmons rebelling against the resistance of the
record companies to put on hip-hop records, which Simmons
knew represented the new heartbeat of a community, a community
that was in rebellion against discrimination, against poverty,
against neglect, against crime-infested neighborhoods. They
were both rebels.
GHARIB: We think of innovators as heroes. Did you like the
people you profiled?
EVANS: I admired all the people I profiled. I don`t know
whether I liked Isaac Singer, for instance, who made a habit
of fathering bastard children and strangling a wife, I don`t
think I did. Samuel Morse had very distinct racist views.
So many of their... we have to put them into the context of
their time. But I did love and admire Thomas Edison.
GHARIB: Do you think that today`s entrepreneurs and innovators
measure up to the legends of the past?
EVANS: I think they do. I think that the Google boys in San
Francisco. I think that Fred Smith in Federal Express, all
of them delivered on an original idea. And for that there
needs to be strength of character, which are truly remarkable.
So I think we are really truly celebrating innovation today
in America. The danger is that the pace of innovation in America
is now slackening. The number of U.S. patents granted to Americans,
the number of Nobel prizes, the number of scientific papers
are all on decline. The number of youngsters taking science
education is in decline. We have to be concerned to regenerate
the spark of innovation, which made America.
GHARIB: Sir Harry, thank you so much for talking to NIGHTLY
BUSINESS REPORT.
EVANS: My pleasure. Thank you.
To Learn More about this topic, click
here.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2004 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/08/04:
"Commentary"-The Attention to the Deficit Disorder
SUSIE GHARIB: Tonight`s commentator says, while soaring deficits
got little attention in this year`s presidential election,
they`ll be high on the agenda in the next. Here`s Mark Zandi,
chief economist at economy.com.
MARK ZANDI, CHIEF ECONOMIST, ECONOMY.COM: Buoyed by his decisive
victory and a more Republican Congress, the president will
move aggressively to significantly change economic policy.
His first move will be to make the tax cuts passed in his
first term permanent. Under current law, the lower personal
and dividend income, capital gains and estate tax rates will
expire in coming years. Not now. The president will also re-introduce
the energy bill that he failed to get through Congress last
year. The legislation provides lucrative tax benefits to energy
companies to expand their exploration and development. These
companies will also gain greater access to Federal lands.
Privatization of Social Security will also quickly make it
onto the legislative agenda. The president will try to entice
young Americans to trade private saving accounts for reductions
in future retirement benefits from the Federal government.
The president will also pursue broader tax reform, which will
include a substantial increase in the contribution limits
to 401(k) accounts and other tax- deferred saving vehicles.
This will be a big step in a broader effort to eventually
move toward a consumption tax. Whatever the merits of these
policies, they will result in a further deterioration in the
already precarious long-term fiscal situation. If the president
gets most of what he wants, which seems entirely possible,
then the cumulative deficit over the next decade will total
a whopping over $6 trillion. While deficits were scarcely
discussed in this election, they will assuredly be economic
agenda item number one in the next presidential election.
This is Mark Zandi.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may
be posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly
Business Report is not and should not be considered as investment
advice. Copyright (c) 2004 Community Television Foundation
of South Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/05/04:
Paul Kangas' "Stocks In The News"
PAUL KANGAS: Gains were hard to come by on Wall Street early today, as a new low
for the dollar against the euro put stocks on the defensive. The Dow fell
about 15 points at the outset of trading, while the NASDAQ Index was off a
fraction. The market showed a slight improvement as the day wore on thanks
to continuing weakness in oil prices, but buyers were very cautious ahead
of Wednesday`s Federal Reserve meeting. The Dow Industrial average closed
with a 3 3/4 point gain at 10,391.31. The NASDAQ Composite edged a fraction
higher at 2039.25. Standard & Poor`s 500 Index down 1 1/4 at 1164.89. the
Treasury market saw weakness across the board. The 10-year note fell
12/32nds, lifting the yield to 4.22 percent.
Big board volume leader on 29 million shares, Pfizer (PFE) down $0.38, on
the close traded as low as $27.85. New York`s attorney general is probing
whether the company promoted drugs for use as other than those approved by
the FDA. Company also is likely to add blackbox (ph) labels on this pain
killer Bextra because it has apparently caused rare but serious skin
reactions.
Then we see Merck & Company (MRK) moving up $0.36, but you heard that the
company`s legal problems are probably just beginning.
Lucent Technologies (LU) $0.07 gain. After the close, Lucent said the SEC
may take civil action against three former employees including a CEO for
alleged bribery in Saudi Arabia, a scheme they had there.
Viacom B (VIA.B) down $0.29.
Time Warner (TWX) moved up $0.08, fifth in volume.
Then we see News Corp B (NWS.B) one issue, B stock, down $0.62.
General Electric (GE) a $0.07 loss.
NorTel Networks (NT) moved up $0.13.
Motorola (MOT) $0.14 drop.
And Sears (S) down $2.75 on profit taking. That stock was up $8.70 Friday
on news that Vornado realty bought a 4.3 percent stake in Sears.
Altria Group (MO), parent of Philip Morris, a $0.36 gain today. Last week,
the stock moved higher after the company said it`s considering splitting
into two or three separate parts. Morgan Stanley today said in parts, the
company could be worth up to $70 a share, well above the current level.
Elan Corporation (ELN), the Irish pharmaceutical and Biogen say that their
multiple sclerosis drug Antegren cut the relapse rate by 66 percent versus
a placebo and the company also thinks (INAUDIBLE) earlier than expected FDA
approval for Antegren.
McDonald`s (MCD) a $0.14 gain. October same store sales worldwide up 6.1
percent and the U.S. same store sales up 7.5 percent for October.
Limited Brands (LTD) up $1.20. The company boosted its third quarter
earnings guidance. It also is sweetening its tender offer for up to $2
billion stock buy back from the $23 a share range. It was high as possibly
$29 a share.
Standard Commercial (STW), which is in the tobacco leaf business, up $1.90.
It`s going to be acquired by Diamond, which is another tobacco company.
It`ll be three shares of Diamond for each share of Standard Commercial.
Today that would have a value of $19.11. New name of the company, Diamond
Standard. Diamond stock was up $0.15 incidentally today.
U.S. Steel (X) up $2.56. Positive comments in a "Barron`s" article. Some
analysts are forecasting $10 a share in earnings for next year.
Conseco (CNO), $1.22 gain there. Third quarter earnings came in at $0.36.
That was $0.02 better than the Street estimate.
FedEx (FDX) up $1.38. The company is boosting its shipping rates by nearly
5 percent. That`s a bigger than an earlier gain this year or boost this
year. Company said that`s because of very strong demand.
Polaris Industries (PII) which makes snowmobiles, ATVs, motorcycles, was
downgraded by Bank of America from "neutral" to a "sell" recommendation.
Microsoft (MSFT) topped the active list on NASDAQ, down $0.03. The
company`s going to pay Novell $536 million to settle an antitrust suit.
Novell stock moved up $0.65 to $7.51.
TASER International (TASR) up $7.63. The Transportation Safety
Administration has approved the use of the company`s stun guns aboard one
major international airline. Turns out it`s Korean Air.
Google (GOOG) up $3.20.
Research In Motion (RIMM) $0.21 gain.
eBay (EBAY) was up $4.01. JPMorgan added eBay to its focus list and has a
12-month target for the stock of $130 a share.
Intel (INTC) $0.13 loss there.
Cisco Systems (CSCO) no change today.
Dell Incorporated (DELL) rose $0.19.
Applied Materials (AMAT) $0.11 gain.
And Yahoo! (YHOO), tenth in volume, was up $0.79.
Those are the stocks in the news tonight.
Nightly
Business Report transcripts are available on-line post broadcast.
The program is transcribed by eMediaMillWorks. Updates may be
posted at a later date. The views of our guests and commentators
are their own and do not necessarily represent the views of
Community Television Foundation of South Florida, Inc. Nightly
Business Report, or WPBT. Information presented on Nightly Business
Report is not and should not be considered as investment advice.
Copyright (c) 2004 Community Television Foundation of South
Florida, Inc. ALL RIGHTS RESERVED. Terms of use.
11/08/04:
Market Stats
NET PERCENT
CLOSE CHANGE CHANGE
DOW CLOSE 10391.31 +3.77 + .0
HIGH 10405.69
LOW 10361.44
NASDAQ COMP. 2039.25 +.31 +.0
HIGH 2044.53
LOW 2033.79
VOLUME 1,358.8
PREVIOUS 1,725.0
UP VOLUME 594.3
DOWN VOLUME 745.0
DOW TRANSPORTS 3581.97 +9.47 + .3
DOW UTILITIES 322.52 +2.45 + .8
CLOSING TICK +495
S&P 500 1164.89 -1.28 - .1
S&P 100 557.30 -.60 - .1
MIDCAP 400 617.66 -2.32 - .4
REUTERS/CRB 284.41 +.75 + .3
NYSE COMPOSITE 6890.00 -20.17 - .3
VALUE LINE 376.54 -1.08 - .3
RUSSELL 2000 602.08 -2.21 - .4
DJW 5000 11395.28 -14.31 - .1
U.S. TREASURIES
5-YEAR NOTE 3.375%
Oct. 15,2009 99 11/32 -8/32 + 3.52
10-YEAR NOTE 4.25%
Aug. 15,2014 100 7/32 -12/32 + 4.22
30-YEAR NOTE 5.375%
Feb. 15, 2031 106 14/32 -19/32 + 4.94
LEHMAN BROS.
LONG BOND INDEX 1747.78 -5.81
DOW CLOSE 10391.31 +3.77 + .0
ADVANCES 1256
DECLINES 2090
NEW HIGHS 210
NEW LOWS 9
NET PERCENT
NYSE MOST ACTIVES 4PM CLOSE CHANGE CHANGE
PFE Pfizer 28.41 -.38 -1.3
MRK Merck & Co 26.57 +.36 +1.4
LU Lucent Tech 3.65 +.07 +2.0
VIAb Viacom "B" 36.20 -.29 -.8
TWX Time Warer 16.81 +.08 +.5
NWS_w News Corp wi "B" 17.58 -.62 -3.4
GE GE 35.12 -.07 -.2
NT Nortel Networks 3.57 +.13 +3.8
MOT Motorola 16.93 -.14 -.8
S Sears 43.13 -2.75 -6.0
NASDAQ CLOSE 2039.25 + 0.31 + .0
VOLUME 1,612.6
PREVIOUS 1,916.7
ADVANCES 1414
DECLINES 1679
NASDAQ ACTIVES
MSFT Microsoft 29.28 -.03 -.1
TASR Taser Intl 54.12 +7.63 +16.4
GOOG Google 172.55 +3.20 +1.9
RIMM Rsch In Motion 77.96 +.21 +.3
EBAY eBay 103.69 +4.01 +4.0
INTC Intel 23.23 -.13 -.6
CSCO Cisco Systems 19.97 unch. unch.
DELL Dell Inc 37.68 +.19 +.5
AMAT Applied Matl 16.39 +.11 +.7
YHOO Yahoo! 37.14 +.79 +2.2
AMEX CLOSE 1319.75 - 7.43 - .6
INDEX SHARES
DIA DIAMONDS TRUST 104.29 +.07 +.1
QQQ NASDAQ 100 37.98 +.02 +.1
SPY S&P DEP.RECEIPTS 117.11 -.17 -.1
STOCKS IN THE NEWS
MO Altria Group 54.42 +.36 +.7
ELN Elan Corp Plc 29.00 +1.12 +4.0
MCD McDonald's 30.20 +.14 +.5
LTD Limited Brands 26.78 +1.20 +4.7
STW Standard Commerc 18.30 +1.90 +11.6
X US Steel 42.97 +2.56 +6.3
CNO Conseco 17.95 +1.22 +7.3
FDX FedEx 93.32 +1.38 +1.5
PII Polaris Industries 61.75 -3.87 -5.9
|
